Company intelligence / Profile preview
Nova Anchora
San Francisco, California, United Statesnovaanchora.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Nova Anchora is advancing NvA-011, a recombinant “genetically correct” type VII collagen protein therapy designed for topical application to restore defective collagen in DEB patients. The program has received FDA orphan drug designation and is currently in preclinical/IND-enabling development with plans to enter clinical trials within two years. Recent funding supports toxicology studies and manufacturing scale-up ahead of IND submission. No clinical results are available yet.
- Therapeutic areas
- Dermatology
- Modalities
- Recombinant protein therapy (recombinant human type VII pro-collagen)Topical biologic gel
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
DEBRA ResearchCureEBEBMRF (Epidermolysis Bullosa Medical Research Foundation)Viking Global InvestorsEB Research Partnership (EBRP)Stanford University licensing partnership
Beyond the preview
Go deeper on Nova Anchora.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nova Anchora.